Skip to main content
OpenTrials
Not Yet Recruiting

NCT Number: NCT06777446

Elective Adhesiolysis vs. a Wait-and-see Policy to Prevent Recurrences After Conservative Treatment of Adhesive Small Bowel Obstruction

Rationale: Adhesive small bowel obstruction (aSBO) is a frequent surgical emergency, associated with 3-8% hospital mortality and a high risk of recurrence (20% at two years of follow-up). ASBO can be treated conservatively or by emergency surgery. In the absence of bowel ischemia or strangulation, conservative treatment is often preferred, to avoid the excess morbidity and mortality from emergency surgery. Recent epidemiological studies, however, demonstrate a considerable higher recurrence risk of aSBO after conservative treatment that is associated with hospital readmissions and lower survival. Elective adhesiolysis following successful conservative treatment might reduce these long-term risks whilst avoiding the high complication rate of emergency surgery.

Objective: The investigators aim to assess the efficacy of elective adhesiolysis following conservative treatment for aSBO as compared to the current state of the art (wait-and-see policy) to prevent long-term recurrence of aSBO. Further the investigators will evaluate quality of life, healthcare and societal costs.

Study design: Multicenter open-label randomized controlled trial, including 380 patients.

Study population: Adult patients who recovered from aSBO by conservative treatment. Patients that are inoperable for medical, anaesthesiological or surgical reasons are excluded. Intervention (if applicable): The intervention of investigation is elective adhesiolysis. Adhesiolysis is an abdominal procedure in which all adhesions are cut, and adhesion prevention applied to reduce the risk of adhesion reformation. The intervention is compared to wait-and-see policy (the current standard treatment)

Main study parameters/endpoints: Primary outcome is recurrence, defined as readmission for obstructive systems with aetiology of adhesions confirmed by CT. The investigators hypothesize a 50% reduction in recurrence in the intervention arm. Secondary outcomes are morbidity from surgery, health-related quality of life (EQ5D), healthcare costs and societal costs (iMCQ and iPCQ)

Nature and extent of the burden and risks associated with participation, benefit and group relatedness:

Patients in the intervention group are exposed to abdominal surgery, which is associated with a moderate risk of minor complications such as wound infection and haemorrhage, and a small risk of severe complications such as iatrogenic bowel injury. According to our hypothesis, a potential benefit is the reduction in the risk of recurrences. Recurrence of aSBO is associated with a risk of readmissions, reinterventions, and also increased long-term mortality.

Not Yet Recruiting

Trial opening soon.

Get Notified

Key information

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

UZ Antwerpen, Antwerp, Belgium

Loading trial locations.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Adult patients aged 18 years and older who have recently recovered from aSBO by small bowel obstruction managed by conservative treatment.
  • Patients who have previously been operated (high a prior risk of adhesions) are required to have no signs of other causes of bowel obstruction on imaging studies (CT-scan).
  • Patients with no previous operation in history (low a prior risk of adhesions) are required to have typical signs for aSBO on imaging studies (abrupt change of bowel calibre, closed loop, or signs of torsion on vessels in the mesentery on CT-scan).

Exclusion criteria

  • Patient who are unfit for reoperation for surgical, anesthesiological or medical reasons as determined by multidisciplinary team assessment or pre-operative screening
  • Patients with active malignancy, reducing life expectancy
  • Pregnancy

Treatment and study plan

Elective Adhesionlysis

Procedure

See descriptions in study arms

Adhesion barrier

Device

At the end of adhesiolysis a barrier will be placed. The adhesion barrier to be used in laparoscopic adhesiolysis is Icodextrin 4% (Adepttm).

Primary outcomes

  1. recurrence of ASBO at 2-years of follow-up

    Time frame: 2 years

    Recurrence is defined as a readmission for symptoms of small bowel obstruction, including lower abdominal pain, bloating and nausea with or without vomiting. In addition imaging by CT-scan should not show indications of other causes of bowel obstruction (such as an incarcerated abdominal wall hernia or tumour), which is over 90% accurate for the diagnosis of ASBO.

Secondary outcomes

  1. Recurrence at 5 year

    Time frame: 5 years

    (identified by record linking[BE] or general practitioner data[NL])

  2. Recurrences needing surgery

    Time frame: 2 years and 5 years

    ASBO recurrence requiring emergency surgery

  3. Morbidity from elective adhesiolysis

    Time frame: 90 days

    Composite of:

    • Serious adverse events and complications, graded by Clavien-Dindo score.
    • Intra-operative events (i.e. bowel injury), graded by ClassIntra®
    • ICU admission
    • Reinterventions within 90 days
  4. Health related quality of life

    Time frame: 2 years

    • Health-related quality of life measured by EQ5D
  5. Gastro-intestinal related quality of life

    Time frame: 2 years

    • Gastro-intestinal related quality of life measured by GIQLI
  6. Healthcare costs

    Time frame: 2 years

    measured by modified iMCQ

  7. Societal costs

    Time frame: 2 years

    measured by modified iMCQ

  8. Cost-effectiveness

    Time frame: 2 years and 5 years

    incremental cost-effectiveness ratio, i.e. cost per QALY

Study contacts

Contact information is provided by the study sponsor or research team.

Richard PG ten Broek, MD, PhD

CONTACT

[email protected]

+31243611111

Sponsors and collaborators

Lead sponsor

Radboud University Medical Center

Other

Collaborators

  • Baxter Healthcare Corporation
  • KCE Belgian Healthcare Knowledge Centre
  • ZonMw: The Netherlands Organisation for Health Research and Development

Registry information

Acronym: AWARE

Important dates

Study start
2025
Primary completion
2029
Study completion
2034
First posted
Jan 15, 2025
Registry last updated
Jan 15, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.